相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats
Ryokichi Koyama et al.
MOLECULAR PHARMACOLOGY (2021)
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
K. El et al.
SCIENCE ADVANCES (2021)
The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight
Mitsugi Ookawara et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Repositioning the Alpha Cell in Postprandial Metabolism
Kimberley El et al.
ENDOCRINOLOGY (2020)
Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety
Hideki Furukawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio et al.
MOLECULAR METABOLISM (2020)
Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
Michael Luckmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity
Hikaru Ueno et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
β Cell tone is defined by proglucagon peptides through cAMP signaling
Megan E. Capozzi et al.
JCI INSIGHT (2019)
Intraislet glucagon signaling is critical for maintaining glucose homeostasis
Lu Zhu et al.
JCI INSIGHT (2019)
Glucagon lowers glycemia when β cells are active
Megan E. Capozzi et al.
JCI INSIGHT (2019)
Incretin hormones: Their role in health and disease
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2018)
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi et al.
ENDOCRINE REVIEWS (2018)
Insulin Secretion Depends on Intra- islet Glucagon Signaling
Berit Svendsen et al.
CELL REPORTS (2018)
THE NEW BIOLOGY AND PHARMACOLOGY OF GLUCAGON
T. D. Mueller et al.
PHYSIOLOGICAL REVIEWS (2017)
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2016)
Peptide YY: more than just an appetite regulator
Shanta J. Persaud et al.
DIABETOLOGIA (2014)
Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes
Kohei Kaku et al.
DIABETES CARE (2013)
GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes
T. Araki et al.
DIABETES OBESITY & METABOLISM (2012)
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
Charles F. Burant et al.
LANCET (2012)
A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents
Jian Luo et al.
PLOS ONE (2012)
Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist
Sean P. Brown et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids
CP Briscoe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Y Itoh et al.
NATURE (2003)
Improved reporter gene assays used to identify ligands acting on orphan seven-transmembrane receptors
K Kotarsky et al.
PHARMACOLOGY & TOXICOLOGY (2003)
分享论文
